As U.S. Food and Drug Administration staffing faces ongoing reductions, numerous pharmaceutical companies are exploring the option of conducting drug development abroad. This shift is prompted by concerns over potential impacts on product development domestically. However, undertaking clinical trials in foreign nations introduces a distinct set of risks and compliance requirements that need careful consideration.
Among the key points to consider are understanding the regulatory environment of the host country, ensuring patient safety standards are comparable to those in the U.S., and managing the complexity of logistical operations across international borders. Additionally, companies should remain vigilant about data integrity and the protection of intellectual property when venturing into international trials. These considerations are crucial for ensuring that foreign clinical trials meet both ethical and legal standards.
For a detailed exploration of these issues and expert insights, visit the full article by attorneys at Morgan Lewis on Law360.